Document is current
Any future updates will be listed below
-
Authors
Leal, Miguel A. https://orcid.org/0000-0002-4797-4617
Sheldon, Todd
Escalante, Keelia
Holm, Mikayle
Galarneau, Michelle
Stromberg, Kurt
Piccini, Jonathan P.
-
Funding
Funding for this research was provided by:
Medtronic
- License Information
-
More Information
Article History
Received: 13 November 2024
Accepted: 3 April 2025
First Online: 27 May 2025
Declarations
:
: MAL: receives grants for clinical research from Medtronic and serves as a consultant to Medtronic and Sanofi; TS, KE, MH, MG, and KS: Employees and shareholders of Medtronic; JPP: supported by R01HL128595 from the National Heart, Lung, and Blood Institute, receives grants for clinical research from Abbott, American Heart Association, Association for the Advancement of Medical Instrumentation, Bayer, Boston Scientific, and Philips, and serves as a consultant to Abbott, Abbvie, Ablacon, Altathera, ARCA Biopharma, Biotronik, Boston Scientific, Bristol Myers Squibb, LivaNova, Medtronic, Milestone, ElectroPhysiology Frontiers, Itamar, Pfizer, Sanofi, Philips, ResMed, and Up-to-Date.
: The AccelAV study protocol was approved by the local ethics committee at each institution.
: All patients in the AccelAV study provided written informed consent.
: Not applicable.
